CARsgen^® has established in-house, vertically integrated manufacturing capabilities for CAR T manufacturing, including plasmids, lentiviral vectors, and CAR T-cell production.

The company has built commercial-scale manufacturing facilities in both China and the U.S. to support clinical trials and commercialization.

Our commercial-scale manufacturing facility in Jinshan, Shanghai, covers a total gross floor area (GFA) of approximately 7,600 square meters and has an estimated capacity to produce autologous CAR T-cell treatments for up to 2,000 patients annually. Additionally, our manufacturing facility in Research Triangle Park, Durham, North Carolina, spans a total GFA of approximately 3,300 square meters and provides CARsgen^® with the capacity to produce autologous CAR T-cell products for 700 patients annually.